ADAPTIMMUNEASSIST

Serial Number 98391186
Registration 7650921
700

Registration Progress

Application Filed
Feb 5, 2024
Under Examination
Approved for Publication
Nov 26, 2024
Published for Opposition
Nov 26, 2024
Registered
Jan 14, 2025

Trademark Image

ADAPTIMMUNEASSIST

Basic Information

Serial Number
98391186
Registration Number
7650921
Filing Date
February 5, 2024
Registration Date
January 14, 2025
Published for Opposition
November 26, 2024
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Jan 14, 2025
Registration
Registered
Classes
005 044

Rights Holder

USWM CT, LLC

16
Address
4441 SPRINGDALE ROAD
LOUISVILLE, KY 40241

Ownership History

Adaptimmune Limited

Original Applicant
99
Abingdon Oxford GB

Adaptimmune Limited

Owner at Publication
99
Abingdon Oxford GB

Adaptimmune Limited

Original Registrant
99
Abingdon Oxford GB

USWM CT, LLC

New Owner After Registration #1
16
LOUISVILLE, KY

Legal Representation

Attorney
Amy B. Berge

USPTO Deadlines

Next Deadline
1838 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250114)
Due Date
January 14, 2031
Grace Period Ends
July 14, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

28 events
Date Code Type Description Documents
Dec 8, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Dec 8, 2025 EWOR I TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED Loading...
Dec 8, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Dec 8, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Dec 8, 2025 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Dec 8, 2025 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Sep 3, 2025 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Jan 14, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jan 14, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Nov 26, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 26, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 20, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 31, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 31, 2024 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Oct 31, 2024 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Oct 31, 2024 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Oct 31, 2024 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Oct 23, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 23, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 23, 2024 ALIE A ASSIGNED TO LIE Loading...
Jul 15, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jun 12, 2024 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 12, 2024 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jun 12, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jun 10, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 2, 2024 MDSM E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Jun 2, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 5, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Cell therapy pharmaceutical preparations; immunotherapy preparations for use in cancer treatment and treatment of autoimmune diseases; Tcell receptors in the nature of pharmaceutical preparations for use in cancer treatment and treatment of autoimmune diseases; pharmaceutical immunotherapy preparations comprising engineered T-cell receptors for use in cancer treatment and treatment of autoimmune diseases; pharmaceutical immunotherapy preparations comprising genes encoding engineered T-cell receptors for use in cancer treatment and treatment of autoimmune diseases
Class 044
Cell therapy medical treatment services; medical services, namely, immunotherapy services; medical services, namely, medical treatment and immunetherapy comprising harvesting a patient's white blood cells, combining white blood cells with an engineered T-cell receptor therapeutic, transducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient

Additional Information

Design Mark
The mark consists of the term "ADAPTIMMUNEASSIST" with bubbles in various sizes forming an arch over the term with the last letter "T" in a stylized form.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
ADAPT IMMUNE ASSIST

Classification

International Classes
005 044